SOURCE: Global Media Networks, Inc.

March 11, 2008 11:43 ET

Global Media Networks, Inc. Announces Biocure Med Inc. Has Obtained Confirmed Positive Results From Pre-Clinical Diabetes Treatment of Proprietary Product DiaCure™

This Imminent Breakthrough Will Accelerate Manufacturing and Distribution Process

PRAEKASA MUENG, THAILAND--(Marketwire - March 11, 2008) - Global Media Networks, Inc. (PINKSHEETS: GLMN) today announced that Biocure Med Inc. has obtained confirmed positive results from the pre-clinical diabetes treatment of its proprietary product DiaCure™.

About DiaCure™ Therapy

The DiaCure™ therapy treats both type 1 and type 2 diabetes patients. The natural component of the DiaCure™ formula allows the patient to not only stabilize their sugar level but also lose weight and suppress their psychological need or urge for sugar. Some of the ingredients facilitate the fast evacuation of toxins and eliminate the recurrent fat overflow in the liver. It also stimulates the pancreas and can replace, in most cases, the insulin injections or conventional oral drugs such as Diabeta and others.

Following the recently obtained positive results, Senior Vice President, R & D and Project Management Alan Rossy, Ph.D. indicated that this new breakthrough for DiaCure™ in the treatment of diabetes will accelerate its manufacturing and distribution process, and the management team has decided to file all requisite documentation to obtain an NPN (Natural Product Number) from the Canadian Health Care Department.

About Canadian Health & Care NPN Regulation

Natural Health Products Regulations include provisions on: definitions, product licensing, site licensing, good manufacturing practices, clinical trials, labelling and packaging requirements, and adverse reaction reporting. The Regulations went into effect on January 1, 2004, which is followed by a transitional period that will span from 2 to 6 years -- 2 years for site licensing and 6 years for products with Drug Identification Numbers (DIN).

The definitions include the definition of a natural health product (including, for example, vitamins, minerals, herbal remedies and homeopathic medicines) and other terms (recommended conditions of use, adverse reaction, etc.) which are key to the functioning of the proposed Regulations.

A product licensing system requires that all licensed products display a product identification number preceded by the prefix NPN, or, in the case of a homeopathic medicine, by the letters DIN-HM on their labels. The number is issued once a product is authorized for sale in Canada by the Natural Health Products Directorate. Product authorization requires either: i) reference to a natural health product monograph (published by the NHPD), or ii) submission of other evidence of safety and health claim. The NHPD is finalizing a standards of evidence framework intended to indicate the type of information that will be necessary to support various health claims, where an NHPD monograph is not available. The Regulations include circumstances for refusing, suspending or cancelling a natural health product license. This system assists Health Canada in ensuring that quality natural health products are sold to the public, and that quick and effective product recalls can be undertaken when necessary.

A system of site licensing has been developed. This system requires that all manufacturers, packagers, labellers, and importers be licensed; sites have procedures in place respecting distribution records and product recalls; where applicable, sites have procedures in place for the handling, storage and delivery of their products, and sites meet good manufacturing practice requirements (commonly known as GMPs, as discussed below). The Regulations also set out circumstances for refusing, suspending or cancelling a site license.

Good Manufacturing Practices (GMPs) are to be employed to ensure product safety and quality. This requires that appropriate standards and practices regarding product manufacture, storage, handling and distribution respecting natural health products be met. The provisions cover: specifications (product), premises, equipment, personnel, sanitation program, operations, quality assurance, stability, records, sterile products, lot or batch samples, and recall reporting.

Standard labelling requirements are established to ensure consumers can make informed choices. Examples of the required label information include: the product name, the quantity of product in the bottle, recommended conditions of use (including such things as: its recommended use or purpose, dosage form, route of administration, recommended dose, and any cautionary statements, warnings, contra-indications and possible adverse reactions associated with the product), as well as any special storage conditions.

About Biocure Med Inc.

Biocure Med Inc. (Biocure) is a biotechnology company specialized in the research, discovery, development and commercialization of medication that potentially cure or stabilize diseases and respond to patients' medical needs. Biocure's proprietary medication product lines under development are centered on the treatment of Diabetes and Alzheimer's disease. Biocure's goal and vision is to become a major player and the world's leading developer of breakthrough therapeutic products in the biotechnology industry. During the last 12 years, Biocure has been built into a fully integrated, commercial-stage biopharmaceutical company that invents, develops and markets safe and effective drugs to treat patients with chronic, debilitating and life-threatening diseases, primarily Diabetes and Alzheimer's. Biocure's new public venue will allow it to expand and rapidly distribute its new breakthrough products in North America and Europe.

For more information please visit the new in-progress Corporate Website at www.biocuremed.com.

To speak with Investor Relations, shareholders may call: David L. Baseheart at 613-482-1778 or via email at ir@biocuremed.com.

Forward-Looking Statements

Please be advised that statements made herein, other than historical data, constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include, among others, potential volatility in the company's stock price, increased competition, customer acceptance of new products and services offered by the company, and uncertainty of future revenue and profitability and fluctuations in its quarterly operating results. Please also be advised that the company's stock is not currently registered with the Securities and Exchange Commission.

Contact Information